Ectoin® Mouth Wash (EML03) in the Prevention and Treatment of Radiation-induced Oral Mucositis

Bitop AG52 enrolled

Overview

This prospective non-interventional comparator study is to collect data on the clinical effectiveness and compliance of Ectoin® Mouth Wash solution (EML03) and to proof superiority to a well-established medical device on the market in the prevention of radiation-induced mucositis. The study doesn´t intervene with routine treatment strategy.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

OTHER

Masking

NONE

Enrollment

Conditions

Oral Mucositis Due to Radiation

Interventions

Ectoin Mouth WashDRUG

According to medical prescription of the instruction for use under consideration (at least 4x1 ampoule (5ml) daily, rinsed in the mouth for at least 30 seconds)

Supersaturated solution of calcium and phosphate ionsDRUG

According to medical prescription of the instruction for use under consideration (4 times a day).

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Individuals regardless of gender older than 18 years * Patients diagnosed with squamous cell carcinomas \[SCCHN\] without metastases of other nonhead and nonneck tumors * Patients receiving radiotherapy with a Karnofsky performance index \>70% * Absence of any sign of oral mucositis at baseline (visit 1) * A definitive or postoperative treatment * Radiation therapy dosage: Limitation dose rate of 60-70 Gy * Radiotherapy of 6-7 weeks duration Exclusion Criteria: * Subjects younger than 18 years * Hypersensitivity to Ectoin® or any of the other ingredients of the mouth wash * Pregnancy or breastfeeding women * Any disease that can, in the opinion of the treating physician, affect the outcome of the observational trial * Patients who had a history of previous radiotherapy in head-neck region or chemotherapy * Massive alcoholic anamnesis * Massive smoker \>20 cigarettes per day at present

Locations (1)

Department of Radiotherapy, National Institute of Oncology

Budapest, Hungary

Outcomes

Primary Outcomes

Change in degree of mucositis (according to WHO classification of mucositis grade) documented by the physician

The degree of oral mucositis will be assessed as follow: grade 0, no signs or symptoms; grade 1, oral soreness and erythema; grade 2, oral erythema, ulcers and solid diet tolerated; grade 3, oral ulcers and liquid diet only; grade 4, oral alimentation impossible

Time frame: Visit 1 (day 0), Visit 2 (after 14 days), Visit 3 (after 28 days), Visit 4 (after 42 days), Visit 5 (28 days after the last RT)

Change in mucositis symptoms dry mucosa, irritation of mucosa, coated tongue, unpleasant breath, decreased saliva release, pain, swelling, ulcer, difficulty to speak and difficulty to eat and dring by using a Numeric Rating Scale

Mucositis symptoms will be measured by using a 4-point scale ranging from 0 (no symptoms) to 3 (severe symptoms).

Time frame: day 0, day 14, day 26, day 42, Visit 5 (28 days after the last RT)

Secondary Outcomes

Number of patients with treatment-related adverse events will be assessed by using the Suspect Adverse Reaction Report Form (CIOMS Form I)

All occuring adverse events/serious adverse events will be documented during the entire study period.

Time frame: within 28 days after starting radiotherapy

Changes in Karnofsky status over time by using the Karnofsky Performance Scale (KPS)

The KPS index allows patients to be classified as to their functional impairment and describes a patient's functional status as a comprehensive 11-point scale correlating to percentage values ranging from 100% (no symptoms) to 0% (death).

Time frame: Visit 1 (day 0), Visit 2 (after 14 days), Visit 3 (after 28 days), Visit 4 (after 42 days), Visit 5 (after 28 days after the last RT)

Tolerability assessment by using a subsequent patient questionnaire

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.